To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Additional recommended knowledge
Politor contains two oral antihyperglycemic agents (pioglitazone hydrochloride and metformin hydrochloride) with different mechanisms of action to improve glycemic control in patients with Diabetes mellitus type 2.
Indication Politor is indicated as an adjunct to diet and exercise:
Dosage and administration
Recommended dose Use of antihyperglycemic agents in the management of type 2 diabetes should be individualized on the basis of effectiveness and tolerability.
Politor should be given with meals; the initial starting dose is either the 15mg/500mg or 15mg/850mg tablet strength once or twice daily, and gradually titrated after assessing adequacy of therapeutic response, while not exceeding the maximum recommended daily dose of pioglitazone 45mg and metformin 2550mg.
Starting dose for patients who initially responded to pioglitazone monotherapy and require additional glycemic control: Based on the usual starting doses of metformin (500mg twice daily or 850mg daily), Politor may be initiated at either the 15mg/500mg twice daily or 15mg/85mg once daily, and gradually titrated after assessing adequacy of therapeutic response.
Starting dose for patients inadequately controlled on metformin monotherapy: Based on the usual starting dose of pioglitazone (15-30mg daily), Politor may be initiated at either the 15mg/500mg or 15mg/850mg once or twice daily, and gradually titrated after assessing adequacy of therapeutic response.
Starting dose for patients switching from combination therapy of pioglitazone plus metformin as separate tablets: Politor may be initiated with either the 15mg/500mg or 15mg/850mg tablet strengths based on the dose of pioglitazone and metformin already being taken.
Use in pregnancy and lactation: Politor(pioglitazone and metformin) should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. There are no adequate and well-controlled studies in pregnant women with combination of pioglitazone and metformin or its individual components. It is not known whether pioglitazone and/or metformin are secreted in human milk. Because many drugs are excreted in human milk, Politor should not be administered to a breastfeeding woman.
Precautions Politor (pioglitazone and metformin) should not be used in patients with type I diabetes or for the treatment of diabetic ketoacidosis and should be used with caution in patients with edema. Serum ALT levels should be evaluated prior to the initiation of therapy with combination of pioglitazone and metformin in all patients and periodically thereafter per the clinical judgment of the health care professional.
Side-effects The most common side-effects are upper respiratory tract infection, diarrhea, combined edema/peripheral edema and headache, respectively. Most clinical adverse events were similar between groups treated with pioglitazone in combination with metformin and those treated with pioglitazone monotherapy.
Contraindications Politor (pioglitazone and metformin) is contraindicated in patients with known hypersensitivity to any components of this combination. These combination also contraindicated in renal disease which may also result from conditions, e.g., acute myocardial infarction, septicemia, acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.
Drug interaction Politor (pioglitazone and metformin) may interact with furosemide, nifedipine, cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) and certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control (e.g., thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid).
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Politor". A list of authors is available in Wikipedia.|